Anti-CD19 CAR Tregs have been applied in humanized mouse GVHD models to demonstrate potent suppression of xenogeneic GVHD clinical manifestations (weights; GVHD scores), as well as demonstrated efficacy to decrease skin allograft rejection [131]. The gene discussed is CD19; the disease is graft versus host disease.